Glucagon-like peptide-1 (GLP-1) receptor agonists

Findings from a meta-analysis indicate that Asian people may derive greater cardiovascular benefit from SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists than their White counterparts.

Phase 2 study results suggest that add-on treatment with an anti-IL-21 antibody plus liraglutide could preserve endogenous insulin secretion in people with recent-onset type 1 diabetes.

The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors when given a higher semaglutide dose than is currently approved.

Add-on treatment with subcutaneous semaglutide 2.4 mg produces a marked increase in weight loss for people without diabetes undertaking an intensive lifestyle intervention to combat obesity, report the STEP 3 investigators in JAMA.

Findings from a pilot study suggest that the GLP-1 receptor agonist liraglutide might be beneficial for the management of obesity in people with schizophrenia, schizoaffective disorder, or first-episode psychosis.

Findings of the STEP 1 study show marked weight loss in people with obesity but without type 2 diabetes during over a year of treatment with a high dose of semaglutide.

A network meta-analysis highlights the impact of individual risk profiles on the absolute benefits offered by GLP-1 receptor agonists and SGLT2 inhibitors for people with type 2 diabetes.

Participants in the REWIND trial achieved a significant reduction in total cardiovascular disease burden with dulaglutide versus placebo, report the investigators.

Dulaglutide doses of 3.0 and 4.5 mg are significantly more efficacious than the standard doses, with similar safety profiles, report the AWARD 11 investigators.

Dulaglutide is associated with better treatment persistence and lower rates of treatment modification versus other glucagon-like peptide‑1 receptor agonists in people with type 2 diabetes, suggests a study of Swedish health registries.

Treatment with semaglutide can lead to resolution of nonalcoholic steatohepatitis in people with or without type 2 diabetes, show phase 2 trial findings, although a question mark remains over its effect on fibrosis.

Geographic remoteness is strongly associated with a reduced likelihood of being prescribed the most recent classes of glucose-lowering medications, find Australian researchers.

Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonists could enable some people with type 2 diabetes to discontinue insulin therapy, suggest findings from the pilot INSPIRE study.

Semaglutide has the potential to improve kidney outcomes in people with type 2 diabetes, a post-hoc analysis of the SUSTAIN 1–7 trials shows.

Results from the D-LIFT trial suggest a reduction in liver fat content when dulaglutide, a glucagon-like peptide-1 receptor agonist, is added to standard care treatment in people with concurrent type 2 diabetes and non-alcoholic fatty liver disease.

Older patients and those with cardiovascular disease are most likely to have an increased risk for lower limb amputation when newly prescribed canagliflozin, relative to a GLP-1 receptor agonist, research shows.

A wide-ranging network meta-analysis published in the Annals of Internal Medicine reveals critical knowledge gaps in the use of glucose-lowering medications in people with type 2 diabetes.

Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.

A phase 1 study of a novel glycosylated Fc-fused glucagon-like peptide-1 receptor agonist suggests it could deliver similar blood glucose-lowering efficacy but with fewer gastrointestinal side effects relative to existing medications in the class.

Glucose-lowering drugs or strategies reduce the risk for major adverse cardiovascular events and death in people with or at risk for type 2 diabetes, but their impact on heart failure may depend on weight loss, shows an updated systematic review and meta-analysis.